Clinical trials: sponsored by ECOG-ACRIN Cancer Research Group
Mantle Cell Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete…
- Trial name
- NCT03267433
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate
- Where
- 375 sites in United States, Saudi Arabia
- Volunteers
- 689 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Liver Lymphoma, Mantle Cell Lymphoma
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell…
- Trial name
- NCT04115631
- Testing
- Acalabrutinib, Bendamustine, Bendamustine Hydrochloride
- Where
- 504 sites in United States
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor…
- Conditions
- Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT06538038
- Testing
- Osimertinib, Osimertinib + Chemotherapy
- Where
- 146 sites in United States
- Volunteers
- 200 people
- Sponsor
- PrECOG, LLC.
Breast Carcinoma
Mobile Health for Adherence in Breast Cancer Patients
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication…
- Trial name
- NCT06112613
- Testing
- Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring
- Where
- 506 sites in United States, Puerto Rico
- Volunteers
- 390 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Pancreatic Neoplasm
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers.
- Trial name
- NCT04239573
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 429 sites in United States, Canada and 2 more
- Volunteers
- 770 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Carcinoma
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.
- Trial name
- NCT04597359
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
- Where
- 353 sites in United States, Guam and 1 more
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
This clinical trial gathers information about adolescents and young adults (AYA) and patient reported outcomes data in Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) trials to…
- Trial name
- NCT05108298
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- 347 sites in United States
- Volunteers
- 500 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Squamous Cell Carcinoma of the Penis, Usual Type
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment.
- Trial name
- InPACT (NCT02305654)
- Testing
- ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01824836
- Testing
- anastrozole
- Where
- 2 sites in United States
- Volunteers
- 1,046 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04423211
- Testing
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography
- Where
- 341 sites in United States
- Volunteers
- 804 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Smoldering Plasma Cell Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma.
- Trial name
- NCT03937635
- Testing
- Daratumumab, Dexamethasone, Lenalidomide
- Where
- 748 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone).
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Trial name
- NCT04566328
- Testing
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone
- Where
- 647 sites in United States, Puerto Rico
- Volunteers
- 1,450 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Glioblastoma, IDH-Wildtype
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma.
- Trial name
- GABLE (NCT06319027)
- Testing
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
This phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating…
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma
- Trial name
- NCT07765433
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 336 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Acute Promyelocytic Leukemia With PML-RARA, t(15;17)
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
This clinical trial studies how well simplified patient care strategy works in decreasing early death in patients with acute promyelocytic leukemia.
- Trial name
- NCT03253848
- Testing
- Simplified Patient Care Strategy, Laboratory Biomarker Analysis
- Where
- 294 sites in United States, Puerto Rico
- Volunteers
- 202 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Carcinoma
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood.
- Trial name
- NCT04484818
- Testing
- Darolutamide, Goserelin Acetate, Leuprolide Acetate
- Where
- 115 sites in United States
- Volunteers
- 27 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer (Adenocarcinoma)
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach…
- Trial name
- TRIPLE-SWITCH (NCT06592924)
- Testing
- Abiraterone, Enzalutamide, Apalutamide
- Where
- 395 sites in United States, Canada and 2 more
- Volunteers
- 830 people
- Sponsor
- Canadian Cancer Trials Group
Rectal Cancer
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together…
- Trial name
- NEO-RT (NCT06205485)
- Testing
- Leucovorin, Oxaliplatin, Fluoruracil
- Where
- 113 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Canadian Cancer Trials Group
Non-small Cell Lung Cancer
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if…
- Trial name
- CURB2 (NCT06686771)
- Testing
- SBRT, First or second-line standard of care therapy
- Where
- 75 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
This phase II trial compares two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with pancreatic cancer that has spread to…
- Trial name
- NCT04233866
- Testing
- Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride
- Where
- 760 sites in United States
- Volunteers
- 176 people
- Sponsor
- ECOG-ACRIN Cancer Research Group